Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 5, 2005, Pages 995-1007

  Lai, Henry ^a   Sasaki, Tomikazu ^b   Singh, Narenda P ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Artemisinin; Cancer; Iron carrying molecule

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEETHER; ARTEFLENE; ARTELINIC ACID; ARTEMISININ; ARTEMISININ TAGGED IRON CARRYING AGENT; ARTESUNATE; CISPLATIN; DIHYDROARTEMISININ; DOXORUBICIN; ETOPOSIDE; FREE RADICAL; IRON; MITOMYCIN C; PACLITAXEL; STAUROSPORINE; TIOGUANINE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURFACE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON TRANSPORT; LARYNX CARCINOMA; NEUROTOXICITY; NONHUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; ARTEMISININS; DRUG DELIVERY SYSTEMS; HUMANS; IRON; NEOPLASMS; SESQUITERPENES;

EID: 27144556223     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.5.995     Document Type: Review

References (135)

1. HIEN TT, WHITE NJ: Qinghaosu. Lancet (1993) 341:603-608.
2. KLAYMAN DL: Qinghaosu (artemisinin): an antimalarial drug from China. Science (1985) 228:1049-1055.
3. ZHANG F, GOSSER DK JR, MESNICK SR: Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. (1992) 43:1805-1809.
4. KAMCHONWONGPAISAN S, MESHNICK SR: The mode of action of the antimalarial artemisinin and its derivatives. Gen. Pharmacol. (1996) 27:587-592.
5. MESHNICK SR, YANG YZ, LIMA V, KUYPERS F, KAMCHONWONGPAISAN S, YUTHAVONG Y: Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agents chemother. (1993) 37:1108-1114.
6. MESHNICK SR: Is haemozoin a target for antimalarial drugs? Ann. Trop. Med. Parasitol. (1996) 90:367-372.
7. ECKSTEIN-LUDWIG U, WEBB RJ, VAN GOETHEM ID et al.: Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 424:957-961.
8. DHINGRA V, RAO KV, NARASU ML: Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. (2000) 66:279-300.
9. NAVARATNAM V, MANSOR SM, SIT NW, GRACE J, LI Q, OLLIARO P: Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. (2000) 39:255-270.
10. LI Y, WU YL: An over four millennium story behind qinghaosu (artemisinin - a fantastic antimalarial drug from a traditional Chinese herb). Curr. Med. Chem. (2003) 10:2197-2230.
11. AVERY MA, ALVIM-GASTON M, WOOLFREY JR: Synthesis and structure-activity relationships of peroxidic antimalarials based on artemisinin. Adv. Med. Chem. (1999) 4:1125-1217.
12. AVERY MA, MCLEAN G, EDWARDS G, AGER A: Structure-activity relationships of peroxide-based artemisinin antimalarials. Biol. Active Nat. Products (2001) 121-132.
13. JEFFORD CW, FERRO S, MOULIN MC et al.: New chemistry involving 1,2,4-trioxanes related to Qinghaosu. Studies Organic Chem. (Amsterdam) (1986) 26:163-83.
14. O'NEILL PM, POSNER GH: A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. (2004) 47:2945-2964.
15. ROBERT A, MEUNIER B: Is alkylation the main mechanism of action of the antimalarial drug artemisinin? Chem. Soc. Rev. (1998) 27:273-274.
16. VENNERSTROM JL, AGER AL Jr, ANDERSON SL et al.: Assessment of the antimalarial potential of tetraoxane WR 148999. Am. J. Trop. Med. Hyg. (2000) 62:573-578.
17. VENNERSTROM JL, ARBE-BARNES S, BRUN R et al.: Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430:900-904.
18. VROMAN JA, ALVIM-GASTON M, AVERY MA: Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials. Curr. Pharmaceut. Design (1999) 5:101-138.
19. WOERDENBAG HJ, PRAS N, VAN UDEN W, WALLAART TE, BEEKMAN AC, LUGT CB: Progress in the research of artemisinin-related antimalarials: an update. Pharm. World Sci. (1994) 16:169-180.
20. ANDREWS NC: Iron homeostasis: insights from genetics and animal models. Nat. Rev. Genetics (2000) 1:208-217.
21. KWOK JC, RICHARDSON DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit. Rev. Oncol. Hematol. (2002) 42:65-78.
22. MAY WS, CUATRECASAS P: Transferrin receptor: its biological significance. J. Membrane Biol. (1985) 88:205-215.
23. REIZENSTEIN P: Iron, free radicals and cancer. Med Oncol. Tumor Pharmacother. (1991) 8:229-233.
24. RAAF HN, JACOBSEN DW, SAVON S, GREEN R: Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. Am. J. Clin. Pathol. (1993) 99:232-237.
25. SHTERMAN N, KUPFER B, MOROZ C: Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiol. (1991) 59:19-25.
26. HSIEH ST, SHI T, REEDER J, RING DB: In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin. Immunol. Immunopathol. (1996) 80:185-193.
27. SINGH NP, LAI H: Selective toxicity of dehydroartemisinin and holotransferrin on human breast cancer cells. Life Sci. (2001) 70:49-56.
28. BILZER T, STAVROU D, DAHME E et al.: Morphological, immunocytochemical and growth characteristics of three human glioblastomas established in vitro. Virchows Arch. A Pathol. Anat. Histopathol. (1991) 418:281-293.
29. PRIOR R, REIFENBERGER G, WECHSLER W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch. A Pathol. Anat. Histopathol. (1990) 416:491-496.
30. RECHT L, TORRES CO, SMITH TW, RASO V, GRIFFIN TW: Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg. (1990) 72:941-945.
31. SUAREZ N, ERIKSSON H: Receptor-mediated endocytosis of a manganese complex of transferrin into neuroblastoma (SHSY5Y) cells in culture. J. Neurochem. (1993) 61:127-131.
32. NICOLSON GL, MENTER DG: Trophic factors and central nervous system metastasis. Cancer Metastasis. Rev. (1995) 14:303-321.
33. EFFERTH T, DUNSTAN H, SAUERBREY A, MIYACHI H, CHITAMBAR CR: The anti-malarial artesunate is also active against cancer. Int. J. Oncol. (2001) 18:767-773.
34. FISHWICK J, MCLEAN WG, EDWARDS G, WARD SA: The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chem. Biol. Interact. (1995) 96:263-271.
35. EFFERTH T, RAMIREZ T, GEBHART E, HALATSCH ME: Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol. (2004) 67:1689-1700.
36. CALZOLARI A, DEAGLIO S, SPOSI NM et al.: Transferrin receptor 2 protein is not expressed in normal erythroid cells. Biochem. J. (2004) 381(Pt 3):629-634.
37. KAWABATA H, NAKAMAKI T, IKONOMI P, SMITH RD, GERMAIN RS, KOEFFLER HP: Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood (2001) 98:2714-2719.
38. LAZARUS AH, BAINES MG: A rapid and efficient microtechnique for the analysis of functional transferrin receptors on tumor cells. J. Immuno. Meth. (1985) 79:213-221.
39. RUDOLPH NS, OHLSSON-WILHELM BM, LEARY JF, ROWLEY PT: Single-cell analysis of the relationship among transferrin receptors, proliferation, and cell cycle phase in K562 cells. Cytometry (1985) 6:151-158.
40. TESTA EP, TESTA U, SAMOGGIA P, SALVO G, CAMAGNA A, PESCHLE C: Expression of transferrin receptors in human erythroleukemic lines: regulation in the plateau and exponential phase of growth. Cancer Res. (1986) 46:5330-5334.
41. PERL A, LOONEY RJ, RYAN DH, ABRAHAM GN: The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing. J. Immunol. (1986) 136:4714-4720.
42. TAETLE R, HONEYSETT JM, TROWBRIDGE I: Effects of antitransferrin receptor antibodies on growth of normal and malignant myeloid cells. Int. J. Cancer. (1983) 32:343-349.
43. BERGAMASCHI G, CAZZOLA M, DEZZA L, SAVINO E, CONSONNI L, LAPPI D: Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). Br. J. Haematol. (1988) 68:379-384.
44. SIZENSKY JA, BARABAS K, FAULK WP: Characterization of the anti-cancer activity of transferrin-adriamycin conjugates. Am. J. Reprod. Immunol. (1992) 27:163-166.
45. LAI H, SINGH NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. (1995) 91:41-46.
46. SINGH NP, LAI H: Artemisinin induces apoptosis in human cancer cells. Anti-Cancer Res. (2004) 24:2277-2280.
47. EFFERTH T, BENAKIS A, ROMEROS MR et al.: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Rad. Biol. Med. (2004) 37:998-1009.
48. MOORE JC, LAI H, LI J-R et al.: Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett. (1995) 98:83-87.
49. BEEKMAN AC, WIERENGA PK, WOERDENBA HJ et al.: Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. Planta Med. (1998) 64:615-619.
50. BEEKMAN AC, WOERDENBA HJ, VAN UDEN W, PRAS N, KONINGS AWT, WIKSTROM HV: Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells. J. Pharm. Pharmacol. (1997) 49:1254-1258.
51. CHEN HH, ZHOU HJ, FANG X: Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. (2003) 48:231-236.
52. DELL'EVA R, PFEFFER U, VENE R et al.: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. (2004) 68:2359-2366.
53. EFFERTH T, DAVEY M, OLBRICH A, RUCKER G, GEBHART E, DAVEY R: Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MDR1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cell Mol. Dis. (2002) 28:160-168.
54. EFFERTH T, OESCH F: Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. (2004) 68:3-10.
55. JEYADEVAN JP, BRAY PG, CHADWICK J et al.: Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10-beta-(2-hydroxyethyl) deoxoartemisinin. J. Med. Chem. (2004) 47:1290-1298.
56. LEE CH, HONG H, SHIN J et al.: NMR studies on novel antitumor drug candidates, deoxoartemisinin and carboxypropyldeoxoartemisinin. Biochem. Biophy. Res. Comm. (2000) 274:359-369.
57. LI Y, SHAN F, WU JM et al.: Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg. Med. Chem. Lett. (2001) 11:5-8.
58. MUKANGANYAMA S, WIDERSTEN M, NAIK YS, MANNERVIK B, HASLER JA: Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int. J. Cancer (2002) 97:700-705.
59. POSNER GH, PLOYPRADITH P, PARKER MH et al.: Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. J. Med. Chem. (1999) 42:4275-4280.
60. POSNER GH, PARK IH, SUR S et al.: Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J. Med. Chem. (2003) 46:1060-1065.
61. POSNER GH, MCRINER AJ, PARK IH et al.: Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J. Med. Chem. (2004) 47:1299-1301.
62. REUNGPATTHANAPONG P, MANKHETKORN S: Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC/adr resistant cell lines. Biol. Pharm. Bull. (2002) 25:1555-1561.
63. SADAVA D, PHILLIPS T, LIN C, KANE SE: Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. (2002) 179:151-156.
64. SUN WC, HAN JX, YANG WY, DENG DA, YUE XF: Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Chung Kuo Yao Li Hsueh Pao (1992) 13:541-543.
65. WOERDENBAG HJ, MOSKAL TA, PRAS N et al.: Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. Prod. (1993) 56:849-856.
66. WU JM, SHAN F, WU GS et al.: Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group. Eur. J. Med. Chem. (2001) 36:469-479.
67. SINGH NP, VERMA KB: Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch. Oncol. (2002) 10:279-280.
68. BERGER TG, DIECKMANN D, EFFERTH T et al.: Artesunate in the treatment of metastatic uveal melanoma-first experience. Oncol. Rep. (In press).
69. CHEN HH, YOU LL, LI SB: Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett. (2004) 211:163-173.
70. CHEN HH, ZHOU HJ, WANG WQ, WU GD: Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother. Pharmacol (2004) 53:423-432.
71. CHEN HH, ZHOU HJ, WU GD, LOU XE: Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacol. (2004) 71:1-9.
72. HEFFELFINGER SC, GEAR RB, SCHNEIDER J et al.: TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen. Lab. Invest. (2003) 83:1001-1011.
73. OH S, JEONG IH, AHN CM, SHIN WS, LEE S: Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. Bioorg. Med. Chem. (2004)12:3783-3790.
74. WARTENBERG M, WOLF S, BUDDE P et al.: The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab. Invest. (2003) 83:1647-1655.
75. BENAKIS A, PARIS M, LOUTAN L, PLESSAS CT, PLASSAS ST: Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg. (1997) 56:17-23.
76. KAMCHONWONGPAISAN S, MCKEEVER P, HOSSLER P, ZIFFER H, MESHNICK SR: Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am. J. Trop. Med. Hyg. (1997) 56:7-12.
77. BREWER TG, GRATE SJ, PEGGINS JO et al.: Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. (1994) 51:251-259.
78. HOFHEINZ W, BURGIN H, GOCKE E et al.: Ro 42-1611 (arteflene), a new effective antimalarial: chemical structure and biological activity. Trop. Med. Parasitol. (1994) 45:261-265.
79. GORDI T, LEPIST EI: Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol. Lett. (2004) 147:99-107.
80. LAI H, SINGH NP: Oral artemisinin prevents and delays the development of 7, 12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. (In press).
81. MASON AB, MILLER MK, FUNK WD et al.: Expression of glycosylated and nonglycosylated human transferrin in mammalian cells. Characterization of the recombinant proteins with comparison to three commercially available transferrins. Biochem. (1993) 32:5472-5479.
82. SPIK G, FOURNET B, BAYARD B et al.: Structure of the glycan chain in sero- and lactotransferrin. Arch. Inter. Physiol. Biochim. (1974) 82:791-795.
83. VAN HALBEEK H, DORLAND L, VLIEGENTHART JFG, SPIK G, CHERON A, MONTREUIL J: Structure determination of two oligomannoside-type glycopeptides obtained from bovine lactotransferrin, by 500 MHz proton NMR spectroscopy. Biochim. Biopbys. Acta (1981) 675:293-296.
84. LAI H, SASAKI T, SINGH NP, MESSEYA: Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. (2005) 76:1267-1279.
85. KIM BJ, SASAKI T. Synthesis of O-aminodihydroartemisinin via TMS triflate catalyzed C-O coupling reaction. J. Org. Chem. (2004) 69:3242-3244.
86. GREEN MD, MIUNT DL, TODD GD, CAPOMACCHIA AC: Chemiluminescent detection of artemisinin novel endoperoxide analysis using luminol without hydrogen peroxide. J. Chromatogr. A (1995) 695:237-242.
87. MASUYA T, KOZURU M: Clinical and experimental studies on the metabolism of transferrin. II. Turnover studies with iodine-labelled human transferrin. Kyushu J. Med. Sci. (1963) 14:233-242.
88. FRANKFURT OS, KRISHAN A. Apoptosis-based drug screening and detection of selective toxicity to cancer cells. Anti-Cancer Drug (2003) 17:555-561.
89. VASSILEY IT, KAZMER S, MARKS IM et al.: Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors. Anticancer Drug Des. (2001) 16:7-17.
90. MARTIN VJ, PITERA DJ, WITHERS ST, NEWMAN JD, KEASLING JD: Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat. Biotechnol. (2003) 21:796-802, 2003.
91. ZHAO KC, SONG ZY. Distribution and excretion of artesunate in rats. Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll. (1989) 4:186-188.
92. LI X, FU GF, FAN YR et al.: Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome endostatin complex. World J. Gastroenterol. (2003) 9:262-266.
93. LI H, QIAN ZM: Transferrin receptor mediated drug delivery. Med. Res. Rev. (2002) 22:225-250.
94. SINGH M: Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. (1999) 5:443-451.
95. CAVANAUGH PG: Synthesis of chlorin e6-transferrin and demonstration of its light-dependent in vitro breast cancer cell killing ability. Breast Cancer Res. Treat. (2002) 72:117-130.
96. LASKE DW, YOULE RJ, OLDFIELD EH: Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nat. Med. (1997) 3:1362-1368.
97. WEAVER M, LASKE DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. (2003) 65:3-13.
98. BICKEL U, YOSIKAWA T, PARDRIDGE WM: Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. (2001) 46:247-279.
99. EFFERTH T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. (2005) 8:85-97.
100. EFFERTH T, BRIEHL MM, TOME ME: Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. (2003) 23:1231-1235.
101. EFFERTH T, VOLM M: Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In vivo (2005) 19:225-232.
102. ASAWAMAHASAKDA W, ITTARAT I, PU YM, ZIFFER H, MESHNICK SR: Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. (1994) 38:1854-1858.
103. MESHNICK SR: Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. (2002) 32:1655-1660.
104. ROSEN HR: Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview. Neoplasma (1996) 43:357-362.
105. ALOJ L, JOGODA E, LANG L et al.: Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. J. Nucl. Med. (1999) 40:1547-1555.
106. IWAGAKI H, MARUTAKA M, YOSHINO T et al.: Gamma-interferon upregulates transferrin receptors and decreases membrane microviscosity in K562 cells. Res. Commun. Mol. Pathol. Pharmacol. (1996) 92:191-200.
107. ZHOU M, LIAO QK, LI FY et al.: Erythropoietin increases transferrin receptor expression and the impact of erythropoietin on K562 leukemic cell cycle Zhonghua Er Ke Za Zhi (2003) 41:528-530.
108. 2+ regulates the cellular iron uptake in K562 cells. Cell Calcium (2003) 33:257-266.
109. KRUNGKRAI SR, YUTHAVONG Y: The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress. Roy. Soc. Trop. Med. Hyg. (1989) 81:710-714.
110. LEVANDER OA, AGER AL Jr., MORRIS VC, MAY RG: Qinghaosu, dietary vitamin E, selenium, and cod liver oil: effect on the susceptibility of mice to the malarial parasite Plasmodium yoelii. Am. J. Clin. Nutr. (1989) 50:346-352.
111. MESHNICK SR, TSANG TW, LIN FB et al.: Activated oxygen mediates the antimalarial activity of qinghaosu. Prog. Clin. Biol. Res. (1989) 313:95-104.
112. LOWY FD: Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. (2003) 111:1265-1273.
113. WEIGEL LM, CLEWELL DB, GILL SR et al.: Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science (2003) 302:1569-1571.
114. BRAUN V, KILLMANN H: Bacterial solutions to the iron-supply problem. Trend. Biol. Sci. (1999) 24:104-109.
115. BRAUN V: Iron uptake mechanisms and their regulation in pathogenic bacteria. Int. J. Med. Microbiol. (2001) 291:67-79.
116. CORNELISSEN CN: Transferrin-iron uptake by Gram-negative bacteria. Front. Biosci. (2003) 8:d836-847.
117. FARALDO-GOMEZ JD, SANSOM MS: Acquisition of siderophores in Gram-negative bacteria. Nat. Rev. Mol. Cell. Biol. (2003) 4:105-110.
118. GUERINOT ML: Microbial iron transport. Ann. Rev. Microbiol. (1994) 48:743-772.
119. STINTZI A, BARMES C, XU J, RAYMOND KN: Microbial iron transport via a siderophore shuttle: a membrane ion transport paradigm. Proc. Natl. Acad. Sci. USA (2000) 97:10691-10696.
120. GRAY-OWEN SD, SCHRYVERS AB: Bacterial transferrin and lactoferrin receptors. Trend Microbiol. (1996) 4:185-191.
121. MODUN B, EVANS RW, JOANNOU CL, WILLIAMS P: Receptor-mediated recognition and uptake of iron from human transferrin by Staphylococcus aureus and Staphylococcus epidermidis. Infect. Immun. (1998) 66:3591-3596.
122. HAMMERSCHMIDT S, BETHE G, REMANE PH, CHHATWAL GS: Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect. Immun. (1999) 67:1683-1687.
123. BRITIGAN BE, LEWIS TS, MCCORMICK ML, WILSON ME: Evidence for the existence of a surface receptor for ferriclactoferrin and ferrictransferrin associated with the plasma membrane of the protozoan parasite Leishmania donovani. Adv. Exp. Med. Biol. (1998) 443:135-140.
124. ALDERETE JF, PETERSON KM, BASEMAN JB: Affinities of Treponema pallidum for human lactoferrin and transferrin. Genitourin. Med. (1988) 64:359-363.
125. TRYON VV, BASEMAN JB: The acquisition of human lactoferrin by Mycoplasma pneumoniae. Microb. Pathog. (1987) 3:437-443.
126. REDHEAD K, HILL T, CHART H: Interaction of lactoferrin and transferrins with the outer membrane of Bordetella pertussis. J. Gen. Microbiol. (1987) 133:891-898.
127. PETERSON KM, ALDERETE JF: Iron uptake and increased intracellular enzyme activity follow host lactoferrin binding by Trichomonas vaginalis receptors. J. Exp. Med. (1984) 160:398-410.
128. DHAENENS L, SZCZEBARA F, HUSSON MO: Identification, characterization, and immunogenicity of the lacroferrin-binding protein from Helicobacter pylori. Infect. Immun. (1997) 65:514-518.
129. SHOEB HA, TAWFIK AF, SHIBL AM, EL-FERALY FS: Antimicrobial activity of artemisinin and its derivatives against anaerobic bacteria. J. Chemother. (Firenze, Italy) (1990) 2:362-367.
130. DHINGRA V, PAKKI SR, NARASU ML: Antimicrobial activity of artemisinin and its precursors. Curr. Sci. (2000) 78:709-713.
131. OLAKAMI O, SCHLESINGER LS, AHMED A, BRITIGAN BF: The nature of extracellular iron influences iron acquisition by Mycobacterium tuberculosis residing within human macrophage. Infect. Immun. (2004) 72:2032-2038.
132. MILLER MJ, MALOUIN F: Microbial iron chelators as drug delivery agents: the rational design and synthesis of siderophore-drug conjugates. Acc. Chem. Res. (1993) 26:241-249.
133. MILLER MJ, GHOSH M: Synthesis and in vitro antibacterial activity of spermine-based catechol- and hydroxamate-containing siderophore-vancomycin conjugates. Bioorgan. Med. Chem. (1996) 4:43-48.
134. MILLER MJ, LU Y: Synthesis and studies of multiwarhead siderophore-5-fluorouridine conjugates. Bioorgan. Med. Chem. (1999) 7:3025-3038.
135. KOSMAN DJ: Molecular mechanisms of iron uptake in fungi. Mol. Microbiol. (2003) 47:1185-1197.